#1 Clinical Trials Search in Europe

Milvexian

Milvexian is an investigational oral anticoagulant drug being studied in various clinical trials. These trials aim to evaluate its effectiveness, safety, and potential uses in preventing blood clots in different patient populations. The studies are exploring Milvexian’s properties, interactions with other medications, and comparing it to existing anticoagulants.

Table of Contents

What is Milvexian?

Milvexian is a new anticoagulant medication currently being studied for its potential to prevent blood clots and treat various cardiovascular conditions. It is also known by the alternative names JNJ-70033093 and BMS-986177[1][2]. An anticoagulant is a type of drug that helps prevent blood from clotting too easily, which can be beneficial in certain medical conditions.

How Does Milvexian Work?

Milvexian works by inhibiting a specific protein in the blood called Factor XIa. This protein plays a role in the blood clotting process. By blocking Factor XIa, Milvexian can help prevent excessive blood clotting without affecting the body’s ability to form necessary clots to stop bleeding[3]. This targeted approach may offer advantages over other anticoagulants in terms of efficacy and safety.

Conditions Treated with Milvexian

Milvexian is being studied for its potential use in several cardiovascular conditions, including:

  • Atrial Fibrillation: A heart rhythm disorder that increases the risk of stroke[4]
  • Acute Coronary Syndrome: A term for conditions where blood flow to the heart is suddenly reduced, including heart attacks[3]
  • Ischemic Stroke: A type of stroke caused by a blood clot blocking blood flow to the brain[5]
  • Transient Ischemic Attack (TIA): Often called a “mini-stroke,” this is a temporary blockage of blood flow to the brain[5]

Ongoing Research and Clinical Trials

Milvexian is currently undergoing extensive research to evaluate its effectiveness and safety. Several clinical trials are in progress, including:

  • A study comparing Milvexian to placebo in patients who have recently experienced an acute coronary syndrome[3]
  • A trial comparing Milvexian to another anticoagulant called apixaban in patients with atrial fibrillation[4]
  • Research on Milvexian’s ability to prevent recurrent strokes in patients who have had an ischemic stroke or high-risk TIA[5]
  • Studies to understand how Milvexian interacts with other medications, such as atorvastatin (a cholesterol-lowering drug)[2]

How is Milvexian Administered?

Milvexian is designed to be taken orally, typically in the form of tablets or capsules. Depending on the specific condition being treated and the stage of research, it may be administered once or twice daily[1][4]. The exact dosage and frequency will be determined by healthcare providers based on ongoing research findings and individual patient needs.

Safety and Side Effects

As with all medications, researchers are closely monitoring the safety of Milvexian and any potential side effects. While specific side effect profiles are still being established through clinical trials, common concerns with anticoagulants include:

  • Increased risk of bleeding
  • Bruising more easily
  • Gastrointestinal issues

One study is specifically looking at how to reverse the effects of Milvexian in case of emergency bleeding situations, which is an important safety consideration for anticoagulant medications[6].

Drug Interactions

Researchers are studying how Milvexian interacts with other medications. For example, one study is investigating the interaction between Milvexian and atorvastatin, a commonly prescribed cholesterol-lowering medication[2]. Another study is looking at how Milvexian affects the body’s processing of midazolam (a sedative) and certain components of oral contraceptives[7]. Understanding these interactions is crucial for ensuring the safe use of Milvexian alongside other medications.

Aspect Details
Drug Name Milvexian (also known as JNJ-70033093, BMS-986177)
Drug Class Oral Factor XIa inhibitor (anticoagulant)
Administration Oral tablets or capsules, typically once or twice daily
Conditions Studied Acute coronary syndrome, ischemic stroke, transient ischemic attack, atrial fibrillation
Key Outcomes Measured Prevention of major adverse cardiovascular events, safety profile, pharmacokinetics, drug interactions
Comparison Treatments Placebo, apixaban (in some trials)
Notable Studies LIBREXIA-STROKE, studies in atrial fibrillation patients, drug interaction studies
Potential Advantages May offer an alternative to existing anticoagulants with a different mechanism of action
Safety Considerations Bleeding risk (common to all anticoagulants), other potential side effects being evaluated

FAQ

  • What is Milvexian? Milvexian is an investigational oral anticoagulant drug that works by inhibiting Factor XIa in the blood clotting process. It is being studied as a potential new treatment to prevent blood clots in various medical conditions.
  • What conditions is Milvexian being studied for? Milvexian is being studied for several conditions, including acute coronary syndrome, ischemic stroke, transient ischemic attack, and atrial fibrillation. These are all conditions where preventing blood clots is important.
  • How is Milvexian administered? Milvexian is administered orally, typically as tablets or capsules. In some studies, it is given once or twice daily, depending on the specific trial protocol.
  • What are some of the main outcomes being measured in Milvexian trials? Key outcomes being measured include the drug's effectiveness in preventing major adverse cardiovascular events (such as heart attack or stroke), its safety profile, and how it compares to existing anticoagulant treatments. Researchers are also studying its pharmacokinetics (how the body processes the drug) and its interactions with other medications.
  • Are there any known side effects of Milvexian? As with all anticoagulants, bleeding is a potential side effect being closely monitored in Milvexian trials. Other possible side effects are being evaluated through these clinical studies. It's important to note that as an investigational drug, all potential side effects may not yet be known.

Ongoing Clinical Trials on Milvexian

  • Study on Milvexian for Preventing Stroke in Patients with Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

    Not recruiting

    1 1 1
    Investigated drugs:
    Austria Belgium Bulgaria Croatia Czechia Denmark +16

  • Study on Milvexian and Drug Combination for Patients Recovering from a Heart Attack

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Austria Belgium Bulgaria Croatia Czechia Denmark +14

  • Study on Milvexian and Apixaban for Preventing Stroke in Patients with Atrial Fibrillation

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Croatia Czechia Denmark Estonia +13

Glossary

  • Anticoagulant: A type of medication that helps prevent blood clots from forming or growing larger.
  • Factor XIa: An enzyme involved in the blood clotting process that Milvexian targets to prevent clot formation.
  • Acute Coronary Syndrome: A term used to describe a range of conditions associated with sudden, reduced blood flow to the heart.
  • Ischemic Stroke: A type of stroke caused by a blockage in an artery that supplies blood to the brain.
  • Transient Ischemic Attack: A temporary period of symptoms similar to those of a stroke, often called a 'mini-stroke'.
  • Atrial Fibrillation: An irregular and often rapid heart rate that can increase the risk of strokes, heart failure, and other heart-related complications.
  • Pharmacokinetics: The study of how the body processes a drug, including its absorption, distribution, metabolism, and excretion.
  • Major Adverse Cardiovascular Event (MACE): A composite endpoint often used in cardiovascular trials, typically including events such as cardiovascular death, heart attack, and stroke.
  • Bioavailability: The proportion of a drug that enters the circulation when introduced into the body and is able to have an active effect.
  • Placebo: An inactive substance used in clinical trials to compare the effects of a drug against no treatment.

References

  1. https://clinicaltrials.gov/study/NCT04844424
  2. https://clinicaltrials.gov/study/NCT04388501
  3. https://clinicaltrials.eu/trial/study-on-milvexian-and-drug-combination-for-patients-recovering-from-a-heart-attack/
  4. https://clinicaltrials.eu/trial/study-on-milvexian-and-apixaban-for-preventing-stroke-in-patients-with-atrial-fibrillation/
  5. https://clinicaltrials.gov/study/NCT05702034
  6. https://clinicaltrials.gov/study/NCT04543383
  7. https://clinicaltrials.gov/study/NCT05706753